New pill aims to tame dangerous immune storms from cancer therapy

NCT ID NCT05905328

Recruiting now Disease control Sponsor: CytoAgents, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called CTO1681 in 54 adults with diffuse large B-cell lymphoma who are about to receive CAR-T therapy. The drug is taken three times daily for 15 days to prevent or reduce cytokine release syndrome, a potentially severe immune reaction. Researchers will monitor side effects and how well the drug controls CRS.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CTO1681 (a drug taken orally three times daily for 15 days)
What this could lead to: If it works, CTO1681 could reduce the severity of cytokine release syndrome, a common and serious side effect of CAR-T therapy, making treatment safer.
What could go wrong: This is an early-phase trial with only 54 participants, so results may not apply broadly. The drug may not reduce CRS or could cause its own side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOKINE RELEASE SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma cytokine release syndrome prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYTOKINE RELEASE SYNDROME

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States
Duke Cancer Institute
RECRUITING

Durham, North Carolina, 27705, United States
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
Georgia Cancer Center at Augusta University
RECRUITING

Augusta, Georgia, 30912, United States
University of California, Irvine - Chao Family Comprehensive Cancer Center
RECRUITING

Orange, California, 92868, United States
University of Pittsburgh Medical Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.